Because of recently updated recommendations by the American College of Cardiology Foundation and American Heart Association about how to treat patients with cardiovascular disorders with antiplatelet therapy, Michael Weber, MD, discusses his personal recommendations.
Kenneth L. Schaecher, MD, FACP, CPC, briefly explains both the clinical and economic outcomes demonstrated through treatment with these agents, and because a large number of antiplatelet drugs are developing, David Calabrese, RPh, MHP, discusses how newer agents address treatment gaps and have better economic value when compared to older agents.
Although Dr Schaecher agrees with the potential of these new drugs, he concludes that there are still many unanswered questions about the ability of these agents to treat patients at risk for developing cardiometabolic events.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More